Mirabaud & Cie SA Cuts Stake in Pfizer Inc. $PFE

Mirabaud & Cie SA lessened its holdings in shares of Pfizer Inc. (NYSE:PFE) by 11.3% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 11,330 shares of the biopharmaceutical company’s stock after selling 1,449 shares during the quarter. Mirabaud & Cie SA’s holdings in Pfizer were worth $275,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Gould Capital LLC raised its holdings in Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 493 shares during the period. GKV Capital Management Co. Inc. purchased a new position in Pfizer in the first quarter valued at approximately $27,000. North Capital Inc. purchased a new position in Pfizer in the first quarter valued at approximately $28,000. Bayforest Capital Ltd purchased a new position in Pfizer in the first quarter valued at approximately $28,000. Finally, Bernard Wealth Management Corp. purchased a new position in Pfizer in the fourth quarter valued at approximately $30,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of PFE opened at $23.91 on Monday. The business’s fifty day moving average price is $24.79 and its 200 day moving average price is $24.27. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.43. The stock has a market capitalization of $135.94 billion, a PE ratio of 12.72, a price-to-earnings-growth ratio of 0.85 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period last year, the business posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.2%. The ex-dividend date was Friday, July 25th. Pfizer’s dividend payout ratio (DPR) is presently 91.49%.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Berenberg Bank cut their price target on shares of Pfizer from $28.00 to $25.00 and set a “hold” rating on the stock in a report on Thursday, May 29th. Bank of America increased their price objective on shares of Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. HSBC lowered their price objective on shares of Pfizer from $27.00 to $26.00 and set a “buy” rating for the company in a research report on Monday, May 19th. Morgan Stanley increased their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 6th. Finally, Jefferies Financial Group raised their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock a “buy” rating in a research report on Wednesday, May 21st. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Pfizer currently has an average rating of “Hold” and an average price target of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.